news articles

Total number of categories

Total number of articles

Market/Novel Tech

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story

Phase II results for sustained release ranibizumab treatment of AMD indicate patients may only require two ophthalmic visits per year

Anti-VEGF treatment of exudative age-related macular degeneration has represented a paradigm shift in the medical management of the disease however, not all patients obtain the same benefit and the burden of potentially monthly injections  and ophthalmic visits can often reduce the effectiveness of the treatment.  In an effort to overcome some of these challenges, a […]

Read full story

First genome-wide association (GWAS) study on the systemic complement activation system identifies markers potentially significant for treatment of AMD

Researchers based at the Department of Ophthalmology at Radboud University Medical Center, Nijmegen, the Netherlands, have shown that variants of the  CFH and CFHR4 genes are associated with variation in the systemic complement activation system, and thereby potentially relevant to how certain AMD patients may respond to therapeutics based on complement biology.  The research, conducted […]

Read full story

August 16th, 2018: “EURETINA-Brief”© Issue No. 182

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the August 16th, 2018 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story

***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***

EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million.  The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]

Read full story

Findings from an international genomics consortium almost double the number of associated genetic loci and variants for AMD

Research conducted by the International AMD Genomics Consortium (IAMDGC) has recently reported an almost doubling in the number of genetic risk loci associated with age-related macular degeneration (AMD). In a significant publication in the journal Nature Genetics, the research group has reported on an analysis of >12 million gene variants, “including 163,714 directly genotyped, mostly […]

Read full story

Latest News

Book Review